Mymetics: the power of a unique technology to develop next-generation prophylactic vaccines for infectious diseases
Our vaccines are designed to induce protection against early transmission and infection, focusing both on the mucosal immune response as a first-line defense and the systemic humoral (blood) immune response, which, for some pathogens, may be essential for the development of an effective prophylactic vaccine. Our unique approach has resulted in the development of a rich pipeline of 5 vaccine candidates for HIV-1/AIDS, intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncytial Virus (RSV) vaccine. Our delivery platform is being validated through partnership with leading pharmaceutical or research organisations, including Astellas Pharma, PATH-MVI and the Bill and Melinda Gates Foundation. Mymetics Corporation (OTCQB: MYMX) is a Swiss based biotechnology company, with a Research Lab in the Netherlands. The company is registered in the US and trades on the OTCQB.